/
/
/

Vanta Bioscience Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
--32%-41%-80%
----54%
----
-28%-41%-69%-104%

Peer Comparison

Symbol
SAGILITY-A
SYNGENE-A
INDGN-A
IGIL-A
NESCO-A
JUSTDIAL-A
LATENTVIEW-A
CMSINFO-A
MEDIASSIST-A
AWFIS-A
VANTABIO-MT
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
46.81₹21885 Cr22.040.463.18₹925 Cr
397.4₹16169 Cr73.16-0.2216.72₹317 Cr
602.3₹14458 Cr36.074.8322.82₹401 Cr
324.35₹14065 Cr23.073.8415.26₹711 Cr
1,052.5₹7366 Cr17.6814.1966.2₹413 Cr
692.75₹5918 Cr11.7519.5464.36₹497 Cr
268.2₹5504 Cr28.172.3311.5₹198 Cr
242.95₹3918 Cr13.355.2333.07₹303 Cr
343.9₹2567 Cr27.533.7123.84₹88 Cr
260.85₹1835 Cr21.623.3568.94₹71 Cr
19.64₹14 Cr129.332.720.7₹11 L

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
₹6 Cr₹6 Cr₹6 Cr₹6 Cr₹6 Cr₹6 Cr₹6 Cr
₹4 Cr₹9 Cr₹11 Cr₹18 Cr₹18 Cr₹17 Cr₹16 Cr
₹4 Cr₹9 Cr₹11 Cr₹18 Cr₹18 Cr₹17 Cr₹16 Cr
₹10 Cr₹15 Cr₹18 Cr₹24 Cr₹24 Cr₹23 Cr₹22 Cr
-₹7 Cr-₹2 Cr₹1 Cr₹5 Cr₹2 Cr₹99 L₹98 L
₹21 Cr₹29 Cr₹35 Cr₹29 Cr₹23 Cr₹13 Cr₹12 Cr
₹33 Cr₹20 Cr₹12 Cr₹8 Cr₹5 Cr₹50 L₹0
₹1 Cr₹75 L₹97 L₹78 L₹72 L₹59 L₹40 L
₹56 Cr₹50 Cr₹48 Cr₹38 Cr₹29 Cr₹14 Cr₹13 Cr
₹5 Cr₹6 Cr₹4 Cr₹2 Cr₹47 L₹49 L₹46 L
₹13 Cr₹12 Cr₹10 Cr₹9 Cr₹10 Cr₹7 Cr₹3 Cr
₹8 Cr₹5 Cr₹4 Cr₹3 Cr₹4 Cr₹2 Cr₹0
₹0₹65,040₹0₹8 L₹11 L₹24 L₹24 L
₹27 Cr₹23 Cr₹18 Cr₹14 Cr₹15 Cr₹10 Cr₹3 Cr
₹86 Cr₹85 Cr₹85 Cr₹81 Cr₹70 Cr₹49 Cr₹39 Cr
₹70 Cr₹61 Cr₹57 Cr₹45 Cr₹36 Cr₹17 Cr₹13 Cr
₹75 Cr₹69 Cr₹67 Cr₹41 Cr₹33 Cr₹23 Cr₹19 Cr
₹19 Cr₹15 Cr₹10 Cr₹5 Cr₹4 Cr₹2 Cr₹1 Cr
₹55 Cr₹54 Cr₹57 Cr₹36 Cr₹29 Cr₹21 Cr₹18 Cr
₹0₹0₹0₹23 Cr₹19 Cr₹7 Cr₹4 Cr
₹65 L₹64 L₹73 L₹2 Cr₹97 L₹97 L₹35 L
₹91 L₹91 L₹91 L₹0₹0₹0₹0
₹71 Cr₹68 Cr₹69 Cr₹67 Cr₹50 Cr₹29 Cr₹22 Cr
₹0₹0₹0₹0₹0₹0₹2 Cr
₹7 Cr₹8 Cr₹7 Cr₹7 Cr₹10 Cr₹14 Cr₹9 Cr
₹3 Cr₹3 Cr₹2 Cr₹1 Cr₹2 Cr₹1 Cr₹2 Cr
₹22 L₹16 L₹10 L₹22 L₹3 Cr₹20 L₹3 Cr
₹26 L₹20 L₹17 L₹21 L₹4 Cr₹2 Cr₹93 L
₹6 Cr₹6 Cr₹6 Cr₹6 Cr₹2 Cr₹2 Cr₹22 L
₹15 Cr₹17 Cr₹15 Cr₹15 Cr₹20 Cr₹20 Cr₹17 Cr
-₹11 Cr-₹6 Cr-₹3 Cr₹22 L₹5 Cr₹10 Cr₹14 Cr
₹86 Cr₹85 Cr₹85 Cr₹81 Cr₹70 Cr₹49 Cr₹39 Cr
₹17₹24₹28₹38₹38₹37₹35
₹17₹24₹28₹38₹38₹37₹35

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
-₹13 Cr-₹9 Cr-₹10 Cr₹23 L₹59 L₹1 Cr₹1 Cr
₹8 Cr₹10 Cr₹9 Cr₹4 Cr₹3 Cr₹3 Cr₹2 Cr
₹2 Cr₹1 Cr₹1 Cr₹1 Cr₹3 Cr-₹2 Cr-₹5 Cr
-₹2 Cr₹3 Cr-₹63 L₹5 Cr₹7 Cr₹2 Cr-₹1 Cr
-₹2 Cr₹3 Cr-₹63 L₹5 Cr₹7 Cr₹2 Cr-₹1 Cr
-₹7 Cr-₹3 Cr-₹6 Cr-₹17 Cr-₹22 Cr-₹7 Cr-₹5 Cr
₹9 Cr₹69 L₹6 Cr₹9 Cr₹18 Cr₹2 Cr₹10 Cr
₹6 L₹6 L-₹13 L-₹2 Cr₹2 Cr-₹3 Cr₹3 Cr
₹16 L₹10 L₹22 L₹3 Cr₹20 L₹3 Cr₹9 L
₹22 L₹16 L₹10 L₹22 L₹3 Cr₹20 L₹3 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)0.00
Volume (₹)0.00
High (₹)0.00
Upper Circuit20.62
Low (₹)0.00
Lower Circuit18.66
Prev Close19.64
52W High (₹)29.00
Price19.64
52W Low (₹)14.71

Share Market Cap & Key Ratios Overview

M.Cap (₹)13.97 Cr
Div. Yield (%)0.00
PE Ratio129.33
Debt to Equity6.72
Price to Book1.34
Book Value16.51
EPS (TTM)0.15
Face Value10.00
ROE (%)-103.74

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SAGILITY-ANSE
SYNGENE-ANSE
INDGN-ANSE
IGIL-ANSE
NESCO-ANSE
JUSTDIAL-ANSE
LATENTVIEW-ANSE
CMSINFO-ANSE
MEDIASSIST-ANSE
AWFIS-ANSE
VANTABIO-MTNSE
LTP
1W Low
1W High
Market cap (₹)
46.96+0.56 (1.21%)
45.85
47.47
21,885Cr
397.1-6.3 (-1.56%)
395.10
407.50
16,169Cr
602+23.35 (4.04%)
579.95
616
14,458Cr
327.5-11.85 (-3.49%)
321.35
346.50
14,065Cr
1050+1.7 (0.16%)
1028.80
1065.90
7,366Cr
692-12.65 (-1.80%)
688.90
734
5,918Cr
269.3-11.2 (-3.99%)
265.20
278.60
5,504Cr
243.5+0.95 (0.39%)
238.35
253.95
3,918Cr
347.1+13.6 (4.08%)
328
348.50
2,567Cr
261.65+8.1 (3.19%)
250.95
268.70
1,835Cr
19.64+0 (0.00%)
19.64
19.64
14Cr

Vanta Bioscience Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Vanta Bioscience Ltd Quaterly Results Key Takeaways